Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522

Increased oxidative damage to DNA in ALS patients

Bogdanov, M. B., Brown, R. H., Matson, W. R., Smart, R. J., Hayden, D. L., O’Donnell, H. C., Beal, M. F., & Cudkowicz, M. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00349-x · Cited by 334

Oxidative stress in patients with Friedreich ataxia

Schulz, J. B., Dehmer, T., Schöls, L. J., Mende, H. E., Hardt, C., Vorgerd, M., Bürk, K., Matson, W. R., DICHGANS, J., Beal, M. F., et al. (2000) · Neurology · doi:10.1212/wnl.55.11.1719 · Cited by 305

Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease

Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0406 · Cited by 293

Increase of total creatine in human brain after oral supplementation of creatine-monohydrate

Dechent, P., Pouwels, P. J. W., Wilken, B., Hanefeld, F., & Frahm, J. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r698 · Cited by 221

A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2′-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods

Bogdanov, M. B., Beal, M. F., McCabe, D. R., Griffin, R. M., & Matson, W. R. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00113-6 · Cited by 179

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169

Creatine supplementation in Huntington’s disease

Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S. P., Vanhees, L., Leemputte, M. V., Hespel, P., & Dom, R. (2003) · Neurology · doi:10.1212/01.wnl.0000090629.40891.4b · Cited by 163

Creatine therapy for Huntington’s disease: Clinical and MRS findings in a 1-year pilot study

Tabrizi, S. J., Blamire, A. M., Manners, D. N., Rajagopalan, B., Styles, P., Schapira, A. H. V., & Warner, T. T. (2003) · Neurology · doi:10.1212/01.wnl.0000070186.97463.a7 · Cited by 87

Non-Invasive Neurochemical Analysis of Focal Excitotoxic Lesions in Models of Neurodegenerative Illness Using Spectroscopic Imaging

Jenkins, B. G., Brouillet, E., Chen, Y. I., Storey, E., Schulz, J. B., Kirschner, P. B., Beal, M. F., & Rosen, B. R. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199605000-00011 · Cited by 84

Huntington's disease

Walker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,691

Huntington's disease: from molecular pathogenesis to clinical treatment

Ross, C. A., & Tabrizi, S. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,816

Huntington disease

Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641

Huntington disease: natural history, biomarkers and prospects for therapeutics

Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848

Chemical Basis of Reactive Oxygen Species Reactivity and Involvement in Neurodegenerative Diseases

Collin, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102407 · Cited by 852

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., André, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 646

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

Tabrizi, S. J., Reilmann, R., Roos, R. A. C., Dürr, A., Leavitt, B. R., Owen, G. N., Jones, R., Johnson, H. J., Craufurd, D., Hicks, S. L., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70263-0 · Cited by 540

Mitochondrial diseases

Schapira, A. H. V. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61305-6 · Cited by 514

Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases

Trushina, E. V., & McMurray, C. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.056 · Cited by 451

Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease?

de Vries, H. E., Witte, M. E., Hondius, D., Rozemüller, A. J. M., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 436

Mitochondrial Diseases of the Brain

Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 426

Functions and effects of creatine in the central nervous system

Andres, R. H., Ducray, A., Schlattner, U., Wallimann, T., & Widmer, H. R. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.02.035 · Cited by 389

Beyond the brain: widespread pathology in Huntington's disease

van der Burg, J. M. M., Björkqvist, M., & Brundin, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70178-4 · Cited by 362

Creatine: Endogenous Metabolite, Dietary, and Therapeutic Supplement

Brosnan, J. T., & Brosnan, M. E. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093621 · Cited by 347

What Is Nuclear Factor Kappa B (NF-κB) Doing in and to the Mitochondrion?

Albensi, B. C. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00154 · Cited by 341

Oxidative Damage in Huntington's Disease Pathogenesis

Browne, S. E., & Beal, M. F. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.2061 · Cited by 313

Network Organization of the Huntingtin Proteomic Interactome in Mammalian Brain

Shirasaki, D. I., Greiner, E. R., Al-Ramahi, I., Gray, M., Boontheung, P., Geschwind, D. H., Botas, J., Coppola, G., Horvath, S., Loo, J. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.024 · Cited by 297

Mitochondrial Approaches for Neuroprotection

Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294

Nrf2-ARE stress response mechanism: A control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases

Singh, S., Vrishni, S., Singh, B. K., Rahman, I., & Kakkar, P. (2010) · Free Radical Research · doi:10.3109/10715762.2010.507670 · Cited by 305

Mitochondria: A therapeutic target in neurodegeneration

Moreira, P. I., Zhu, X., Wang, X., Lee, H., Nunomura, A., Petersen, R. B., Perry, G. L., & Smith, M. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.007 · Cited by 291

Mitochondria in Huntington's disease

Damiano, M. G., Galvan, L., Déglon, N., & Brouillet, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.012 · Cited by 295

Transcriptional signatures in Huntington's disease

Cha, J.-H. J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.03.004 · Cited by 275

Impaired PGC-1α function in muscle in Huntington's disease

Chaturvedi, R. K., Adhihetty, P. J., Shukla, S., Hennessy, T., Calingasan, N. Y., Yang, L., Starkov, A. A., Kiaei, M., Cannella, M., Sassone, J., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp243 · Cited by 245

Oxidative Stress and Huntington’s Disease: The Good, the Bad, and the Ugly

Kumar, A., & Ratan, R. R. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160205 · Cited by 236

Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases

Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Beal, M. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 237

Huntington's Disease: Can Mice Lead the Way to Treatment?

Crook, Z. R., & Housman, D. E. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.035 · Cited by 236

Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients

Chen, C., Wu, Y., Cheng, M., Liu, J., Lee, Y., Lee, P.-W., Soong, B., & Chiu, D. T.-Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.093 · Cited by 226

PGC-1α, mitochondrial dysfunction, and Huntington's disease

Johri, A., Chandra, A., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.016 · Cited by 227

Proteomic Profiling of Plasma in Huntington's Disease Reveals Neuroinflammatory Activation and Biomarker Candidates

Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Björkqvist, M., Petersén, Å., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., et al. (2007) · Journal of Proteome Research · doi:10.1021/pr0700753 · Cited by 223

Energy deficit in Huntington disease: why it matters

Mochel, F., & Haller, R. G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45691 · Cited by 220

The Spinocerebellar Ataxias

Paulson, H. L. (2009) · Journal of Neuro-Ophthalmology · doi:10.1097/wno0b013e3181b416de · Cited by 220

Mitochondrial Creatine Kinase Activity Prevents Reactive Oxygen Species Generation

Meyer, L. E., Machado, L. B., Santiago, A. P. S. A., da‐Silva, W. S., Felice, F. G. D., Holub, O., de Oliveira, M. F., & Galina, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604123200 · Cited by 213

Synthesis and transport of creatine in the CNS: Importance for cerebral functions

Béard, E., & Braissant, O. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06935.x · Cited by 192

Neuroprotective effects of creatine

Beal, M. F. (2011) · Amino Acids · doi:10.1007/s00726-011-0851-0 · Cited by 196

Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases

Adhihetty, P. J., & Beal, M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8053-y · Cited by 190

Oxidative stress biomarkers in sporadic ALS

Mitsumoto, H., Santella, R. M., Liu, X., Bogdanov, M. B., Zipprich, J., Wu, H., Mahata, J., Kilty, M., Bednarz, K., Bell, D. A., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960801933942 · Cited by 199

Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease [RETIRED]

Armstrong, M. J., & Miyasaki, J. M. (2012) · Neurology · doi:10.1212/wnl.0b013e318263c443 · Cited by 180

Antioxidant gene therapy against neuronal cell death

Navarro-Yepes, J., Zavala-Flores, L. M., Anandhan, A., Wang, F., Skotak, M., Chandra, N., Li, M., Pappa, A., Martínez‐Fong, D., Razo, L. M. D., et al. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.007 · Cited by 182

Machado–Joseph disease/spinocerebellar ataxia type 3

Paulson, H. L. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-51892-7.00027-9 · Cited by 180

Effects of Creatine Supplementation on Brain Function and Health

Forbes, S. C., Cordingley, D. M., Cornish, S. M., Gualano, B., Roschel, H., Ostojić, S. M., Rawson, E. S., Roy, B. D., Prokopidis, K., Giannos, P., et al. (2022) · Nutrients · doi:10.3390/nu14050921 · Cited by 184

Therapeutic interventions for symptomatic treatment in Huntington's disease

Mestre, T., Ferreira, J. J., Coelho, M. M., Rosa, M. M., & Sampaio, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006456.pub2 · Cited by 173

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

Stack, C., Ho, D. J., Wille, E. J., Calingasan, N. Y., Williams, C. R., Liby, K. T., Sporn, M. B., Dumont, M., & Beal, M. F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.017 · Cited by 175

Creatine for treating muscle disorders

Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169

Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants

Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 169

Therapeutic Advances for Huntington’s Disease

Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J. (2020) · Brain Sciences · doi:10.3390/brainsci10010043 · Cited by 170

From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research

Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613021 · Cited by 174

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease

Johri, A., Calingasan, N. Y., Hennessey, T., Sharma, A., Yang, L., Wille, E. J., Chandra, A., & Beal, M. F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr541 · Cited by 163

Development of biomarkers for Huntington's disease

Weir, D. W., Sturrock, A., & Leavitt, B. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70070-9 · Cited by 162

Antioxidants in Huntington's disease

Johri, A., & Beal, M. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.014 · Cited by 163

Exploring the therapeutic role of creatine supplementation

Gualano, B., Artioli, G. G., Poortmans, J. R., & Lancha Junior, A. H. (2010) · Amino Acids · doi:10.1007/s00726-009-0263-6 · Cited by 156

Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers

Politis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P., Scahill, R. I., Turkheimer, F., Tabrizi, S. J., & Piccini, P. P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.011 · Cited by 156

The Role of the Immune System in Huntington’s Disease

Ellrichmann, G., Reick, C., Saft, C., & Linker, R. A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/541259 · Cited by 155

A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions

Kumar, A., & Singh, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00206 · Cited by 154

Mouse models of Huntington's disease and methodological considerations for therapeutic trials

Ferrante, R. J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.04.001 · Cited by 157

Mitoenergetic failure in Alzheimer disease

Parihar, M. S., & Brewer, G. J. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00232.2006 · Cited by 153

Spinocerebellar ataxias: an update

Soong, B., & Paulson, H. L. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3281fbd3dd · Cited by 148

Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy

Matos, C. A., de Almeida, L. P., & Nóbrega, C. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14541 · Cited by 145

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

† (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70262-5 · Cited by 144

Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities

Sbodio, J. I., Snyder, S. H., & Paul, B. D. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7321 · Cited by 147

Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis

Ayala‐Peña, S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.017 · Cited by 147

The Clinical and Genetic Features of Huntington Disease

Sturrock, A., & Leavitt, B. R. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383573 · Cited by 144

Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders

Covarrubias‐Pinto, A., Acuña, A. I., Beltrán, F. A., Torres-Díaz, L., & Castro, M. A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226095 · Cited by 140

Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington’s disease knock-in striatal cells

Ribeiro, M., Rosenstock, T. R., Oliveira, A. M., Oliveira, C. R., & Rego, A. C. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.023 · Cited by 145

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases

Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139

Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease

Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 136

Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation

Chaturvedi, R. K., Calingasan, N. Y., Yang, L., Hennessey, T., Johri, A., & Beal, M. F. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq229 · Cited by 140

Creatine in the central nervous system: From magnetic resonance spectroscopy to creatine deficiencies

Račkayová, V., Cudalbu, C., Pouwels, P. J. W., & Braissant, O. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.11.007 · Cited by 137

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127

Modulation of nucleosome dynamics in Huntington's disease

Stack, E. C., Signore, S. J. D., Luthi‐Carter, R., Soh, B. Y., Goldstein, D. R., Matson, S. A., Goodrich, S., Markey, A., Cormier, K., Hagerty, S. W., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm064 · Cited by 119

The Creatine Kinase/Creatine Connection to Alzheimer′s Disease: CK Inactivation, APP‐CK Complexes and Focal Creatine Deposits

Bürklen, T. S., Schlattner, U., Homayouni, R., Gough, K. M., Rak, M., Szeghalmi, A. V., & Wallimann, T. (2006) · BioMed Research International · doi:10.1155/jbb/2006/35936 · Cited by 129

Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers

Braissant, O. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9433-2 · Cited by 112

Creatine as a booster for human brain function. How might it work?

Rae, C. D., & Bröer, S. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.08.010 · Cited by 112

Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease

Beal, M. F. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70812-0 · Cited by 104

The CREST-E study of creatine for Huntington disease

Hersch, S. M., Schifitto, G., Oakes, D., Bredlau, A., Meyers, C. M., Nahin, R. L., Rosas, H. D., & For the Huntington Study Group CREST-E Investigators and Coordinators (2017) · Neurology · doi:10.1212/wnl.0000000000004209 · Cited by 102

PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease

Rosas, H. D., Doros, G. D., Gevorkian, S., Malarick, K., Reuter, M., Coutu, J., Triggs, T. D., Wilkens, P. J., Matson, W. R., Salat, D. H., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000187 · Cited by 98

Therapy development in Huntington disease: From current strategies to emerging opportunities

Dickey, A. S., & Spada, A. R. L. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38494 · Cited by 98

Creatine for neuroprotection in neurodegenerative disease: end of story?

Bender, A., & Klopstock, T. (2016) · Amino Acids · doi:10.1007/s00726-015-2165-0 · Cited by 96

“Heads Up” for Creatine Supplementation and its Potential Applications for Brain Health and Function

Candow, D. G., Forbes, S. C., Ostojić, S. M., Prokopidis, K., Stock, M. S., Harmon, K. K., & Faulkner, P. (2023) · Sports Medicine · doi:10.1007/s40279-023-01870-9 · Cited by 104

Disturbed energy metabolism and muscular dystrophy caused by pure creatine deficiency are reversible by creatine intake

Nabuurs, C. I. H. C., Choe, C., Veltien, A. A., Kan, H. E., van Loon, L. J. C., Rodenburg, R. J., Matschke, J., Wieringa, B., Kemp, G. J., Isbrandt, D., et al. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.241760 · Cited by 95

A systematic review of the treatment studies in Huntington’s disease since 1990

Bonelli, R. M., & Hofmann, P. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.2.141 · Cited by 93

The application of NMR-based metabonomics in neurological disorders

Holmes, E. C., Tsang, T. M., & Tabrizi, S. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.05.004 · Cited by 92

Kaempferol protects against rat striatal degeneration induced by 3‐nitropropionic acid

Lagoa, R., López-Sánchez, C., Samhan-Arias, A., Gañan, C. M., García-Martínez, V., & Gutiérrez-Merino, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06331.x · Cited by 88

The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?

Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101

Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease.

Chen, C. (2011) · PubMed · Cited by 89

Pharmacologic approaches to the treatment of Huntington's disease

Venuto, C. S., McGarry, A. J., Ma, Q., & Kieburtz, K. D. (2011) · Movement Disorders · doi:10.1002/mds.23953 · Cited by 93

Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA

Guidi, C., Potenza, L., Sestili, P., Martinelli, C., Guescini, M., Stocchi, L., Zeppa, S. D., Polidori, E., Annibalini, G., & Stocchi, V. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.09.018 · Cited by 84

Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases

Lim, J. L., Wilhelmus, M. M. M., de Vries, H. E., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1338-z · Cited by 84

A review of creatine supplementation in age-related diseases: more than a supplement for athletes

Smith, R. N., Agharkar, A. S., & Gonzales, E. B. (2014) · F1000Research · doi:10.12688/f1000research.5218.1 · Cited by 82

Targeting mitochondrial dysfunction in neurodegenerative disease: Part II

Burchell, V., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y., & Plun‐Favreau, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003730434 · Cited by 83

Improvement of Oxidative Stress and Mitochondrial Dysfunction by β-Caryophyllene: A Focus on the Nervous System

Ullah, H., Minno, A. D., Santarcangelo, C., Khan, H. Z., & Daglia, M. (2021) · Antioxidants · doi:10.3390/antiox10040546 · Cited by 81

Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies

Evers, M. M., Toonen, L. J. A., & van Roon‐Mom, W. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8596-2 · Cited by 81

The Phosphocreatine Circuit: Molecular and Cellular Physiology of Creatine Kinases, Sensitivity to Free Radicals, and Enhancement by Creatine Supplementation

Wallimann, T., Tokarska-Schlattner, M., Neumann, D., Epand, R. M., Epand, R. F., Andres, R. H., Widmer, H. R., Hornemann, T., Saks, V. A., Agarkova, I., et al. (2007) · Wiley eBooks · doi:10.1002/9783527621095.ch7 · Cited by 83

Huntington’s Disease Clinical Trials Corner: February 2018

Rodrigues, F. B., & Wild, E. J. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-189001 · Cited by 81

Maternal creatine: does it reach the fetus and improve survival after an acute hypoxic episode in the spiny mouse (Acomys cahirinus)?

Ireland, Z., Dickinson, H., Snow, R. J., & Walker, D. W. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.10.790 · Cited by 78

Mitochondrial Abnormalities and Synaptic Damage in Huntington’s Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics

Sawant, N. A., Morton, H., Kshirsagar, S., Reddy, A. P., & Reddy, P. H. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02556-x · Cited by 74

Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder

Yoon, S., Kim, J. E., Hwang, J., Kim, T.-S., Kang, H. J., Namgung, E., Ban, S., Oh, S., Yang, J., Renshaw, P. F., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.027 · Cited by 71

8OHdG as a marker for Huntington disease progression

Long, J. D., Matson, W. R., Juhl, A. R., Leavitt, B. R., & Paulsen, J. S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.012 · Cited by 71

Milestones in Huntington disease

Shoulson, I., & Young, A. B. (2011) · Movement Disorders · doi:10.1002/mds.23685 · Cited by 70

Creatine may reduce oxidative injury in Huntington's disease

&NA; (2006) · Inpharma Weekly · doi:10.2165/00128413-200615290-00038

Creatine supplementation lowers brain glutamate levels in Huntington?s disease

Bender, A., Auer, D. P., Merl, T., Reilmann, R., Saemann, P., Yassouridis, A., Bender, J., Weindl, A., Dose, M., Gasser, T., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0595-4 · Cited by 129

Creatine supplementation in Huntington’s disease

Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S. P., Vanhees, L., Leemputte, M. V., Hespel, P., & Dom, R. (2003) · Neurology · doi:10.1212/01.wnl.0000090629.40891.4b · Cited by 163

PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease

Rosas, H. D., Doros, G. D., Gevorkian, S., Malarick, K., Reuter, M., Coutu, J., Triggs, T. D., Wilkens, P. J., Matson, W. R., Salat, D. H., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000187 · Cited by 98

Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease

Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0406 · Cited by 293